Videos and webinars

  1. Scaling Quality And Managing Cost Pressures Across CGTs 1/12/2026

    During Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen examined how CGT developers can scale quality organizations without creating unsustainable overhead, while also addressing the distinct cost pressures of cell versus gene therapy manufacturing.

  2. Workforce Readiness And A Final Checklist For Multi-Modal CDMO Selection 1/12/2026

    The closing segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen emphasized that true multi-modal readiness depends as much on people and governance as on facilities and technology. Our experts stressed the importance of a deeply trained, modality-specific workforce, shaped by practical factors such as geographic access to skilled aseptic operators, alongside robust training strategies to build talent where gaps exist.

  3. Choosing The Right CDMO In A Multi-Modal CGT Landscape 1/12/2026

    Our first segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen set the stage for how cell and gene therapy developers are rethinking outsourcing as pipelines expand beyond single modalities, weighing the tradeoffs between using one multimodal CDMO versus multiple specialized partners.

  4. A Better Way For Closed-System Processing In Cell Therapy 12/1/2025

    Small changes in aseptic processing can yield major operational improvements. Streamlining closed-system connections helps reduce contamination risks, supports scalability, and lowers manufacturing costs.

  5. Modular Systems Explained 9/3/2025

    Modular bioprocessing systems offer fast, flexible manufacturing. They require reliable connectors to facilitate, protect, and manage fluid flow from the beginning of the process to final fill-finish.

  6. Innovations In CGT Processing 6/3/2025

    Discover insights into how innovative connectors streamline workflows, save time, and enhance reliability in critical applications, ultimately supporting improved outcomes in cell and gene therapies.

  7. Innovations In Sterile Connectors Transform CGT Bioprocessing 4/21/2025

    Explore advancements in single-use sterile connectors transforming CGT bioprocessing by enhancing fluid handling, reducing contamination, and improving process reliability for next-gen therapies.

  8. Emerging Manufacturing Technologies For Cell Therapies | Audience Q&A 4/15/2025

    Cell & Gene Live’s Audience Q&A always draws valuable questions in real time from our audience. Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio provide detailed responses to audience questions that addressed the importance of vein-to-vein time for non-cancer indications, such as autoimmune diseases.

  9. The Impact Of Cell Therapy Manufacturing On Patient Access And Experience 4/15/2025

    During this segment of Cell & Gene Live, expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio share why improvements in cell therapy manufacturing directly impact the patient experience.

  10. Implementing Emerging Manufacturing Technologies For Cell Therapies 4/15/2025

    In this segment of Cell & Gene Live, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio emphasize the importance of focusing on solving the problem at hand when adopting new technologies.